Olfr65, an olfactory receptor, plays a pivotal role in the complex sensory process of olfaction. This G protein-coupled receptor (GPCR) is expressed in the olfactory sensory neurons within the nasal epithelium, where it functions as a molecular sensor for specific odorants in the environment. The primary role of Olfr65 is to detect and transduce chemical signals from various odor molecules into neuronal signals, initiating a cascade of events that lead to the perception of specific smells. The activation of Olfr65 triggers intracellular signaling pathways, ultimately resulting in the generation of action potentials that convey olfactory information to the brain.
Inhibition of Olfr65 is a nuanced process that involves targeting key components of the olfactory signaling cascade. Various chemicals act as inhibitors by modulating different aspects of the signaling pathways associated with Olfr65 activation. For instance, some inhibitors target ion channels, such as sodium channels, affecting membrane potential dynamics and subsequently hindering Olfr65 responsiveness. Others interfere with intracellular processes, such as the phosphoinositide signaling pathway, by inhibiting phospholipase C. This disruption indirectly influences Olfr65-mediated signaling. Additionally, inhibitors like purinergic receptor antagonists impact intracellular calcium levels, contributing to the inhibition of Olfr65 activation. Other strategies involve influencing calcium influx through L-type calcium channels or disrupting calcium-dependent processes by inhibiting calmodulin kinase II. These mechanisms collectively showcase the complexity of inhibiting Olfr65 and highlight the diverse approaches to modulate olfactory receptor function for research purposes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Amiloride | 2609-46-3 | sc-337527 | 1 g | $296.00 | 7 | |
Sodium channel blocker disrupting ion channel dynamics, modulating the membrane potential and inhibiting Olfr65 responsiveness. | ||||||
Suramin sodium | 129-46-4 | sc-507209 sc-507209F sc-507209A sc-507209B sc-507209C sc-507209D sc-507209E | 50 mg 100 mg 250 mg 1 g 10 g 25 g 50 g | $152.00 $214.00 $728.00 $2601.00 $10965.00 $21838.00 $41096.00 | 5 | |
Purinergic receptor antagonist affecting intracellular calcium levels, leading to inhibition of Olfr65-mediated signaling. | ||||||
(±)-Bay K 8644 | 71145-03-4 | sc-203324 sc-203324A sc-203324B | 1 mg 5 mg 50 mg | $84.00 $196.00 $817.00 | ||
L-type calcium channel agonist influencing calcium influx, indirectly modulating Olfr65 activation. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $182.00 | 25 | |
Calmodulin kinase II inhibitor disrupting calcium-dependent processes, influencing Olfr65 responsiveness. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
PI3-kinase inhibitor impacting the PI3K/Akt signaling pathway, leading to indirect inhibition of Olfr65 activation. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
Src kinase inhibitor affecting tyrosine kinase activity, modulating signaling pathways involved in Olfr65 activation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
MEK inhibitor disrupting the MAPK pathway, indirectly inhibiting Olfr65 activation. | ||||||
KN-62 | 127191-97-3 | sc-3560 | 1 mg | $136.00 | 20 | |
CaMKII inhibitor impacting calcium/calmodulin-dependent processes, influencing Olfr65 responsiveness. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
SERCA pump inhibitor altering calcium homeostasis, indirectly inhibiting Olfr65-mediated signaling. | ||||||